What are some examples of glycans that can be used as biomarkers for cancer?
Best insight from top research papers
Glycans that can be used as biomarkers for cancer include ganglioside GD3 and heparan sulfate glycosaminoglycan in glioma , glycosylated biomarkers such as glycoproteins, glycans, and enzymes in gynecologic cancers , aberrant glycosylation features in tumors and altered glycosylation in cancer cell signaling, tumor progression, metastasis, and immunomodulation , and N-linked glycans such as high-mannose, tri-and tetra-antennary N-glycans in prostate cancer . Additionally, glycomics studies have shown that alterations in glycan compositions and structures, including glycosylation, sialylation, and fucosylation, are common features of tumorigenesis and can be explored as potential biomarkers for cancer diagnosis, prognosis, and therapy .
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
12 Citations | The paper does not provide specific examples of glycans that can be used as biomarkers for cancer. |
| The paper does not provide specific examples of glycans that can be used as biomarkers for cancer. | |
| The paper does not provide specific examples of glycans that can be used as biomarkers for cancer. | |
3 Citations | The paper does not provide specific examples of glycans that can be used as biomarkers for cancer. |
| The paper mentions that specific glycan structures have been established as cancer biomarkers, but it does not provide specific examples of these glycans. |
Related Questions
What are the specific glycan biomarkers that have been identified for the diagnosis of gestational diabetes?5 answersPlasma glycan biomarkers have been identified for the diagnosis of gestational diabetes mellitus (GDM). Studies have highlighted the potential of glycated CD59 (gCD59) as a novel biomarker for GDM diagnosis. Additionally, glycosylated Fibronectin (GFN) has been implicated in various pregnancy complications, including GDM, suggesting altered glycosylation patterns as potential biomarkers for GDM. Furthermore, recent research has shown that specific CpG sites, such as cg11169102, cg21179618, and cg21620107, identified through epigenome-wide association studies, can serve as potential biomarkers for GDM diagnosis. These findings collectively indicate a promising avenue for utilizing glycan biomarkers in the early detection and diagnosis of gestational diabetes.
Why is there glycosylation in cancer associated protein?4 answersGlycosylation is a common post-translational modification in cancer-associated proteins. It plays a critical role in mediating cell-cell interactions, protein-receptor signaling, and protein folding during translation. Aberrant glycosylation, characterized by altered glycan structures, is a hallmark of cancer and is involved in various malignant behaviors of tumors, including proliferation, invasion, metastasis, angiogenesis, and immune modulation. These alterations in glycosylation patterns can lead to micro- and macro-heterogeneity in tumor cells. Furthermore, cancer-associated glycans can modulate the response to targeted therapeutic agents and contribute to the development of therapeutic resistance. Understanding the role of glycosylation in cancer biology has led to the identification of potential glycan-based biomarkers for diagnosis, prognosis, and immunotherapy. Overall, glycosylation in cancer-associated proteins is crucial for regulating fundamental processes and has significant implications for cancer progression and treatment.
How can surface glycoproteins/glycans be extracted from cancer cells?3 answersSurface glycoproteins/glycans can be extracted from cancer cells using various methods. One approach is the use of sodium deoxycholate (SDC) as an acidic labile detergent to release N-glycans from glycoproteins derived from biological samples such as cancer cell lines. This method has been found to be more efficient and unbiased compared to other sample preparation approaches. Another method involves the use of short one-step chloroform-methanol extraction in the presence or absence of water prior to PNGase F deglycosylation. This simple preparative method has been successfully applied to the investigation of N-glycans obtained from small numbers of in vitro cultured cancer cells and tumor tissues, including patient biopsies. These methods provide efficient extraction of surface glycoproteins/glycans, enabling further analysis and characterization of these molecules in cancer cells.
What are the advantages and disadvantages of using glycans as biomarkers for cancer?3 answersGlycans have several advantages as biomarkers for cancer. They can provide extra information for cancer monitoring and enhance the diagnostic power of biomarker-based cancer detection tests. Aberrant glycosylation is a hallmark of neoplastic transformation, and specific glycan structures have been established as cancer biomarkers. Glycans offer a promise of more efficient patient stratification compared to genetic variations. In prostate cancer, glycans have shown huge promise as diagnostic and prognostic biomarkers, and integrating biomarkers across multi-omic platforms, including changes to the glycome, can improve patient stratification. However, there are also disadvantages to using glycans as biomarkers. The lack of reliable blood biomarkers remains a major challenge for early diagnosis in lung cancer. Additionally, the analysis of glycans requires specialized techniques and technologies, which may limit their widespread use in clinical settings.
Cancer Biomarkers5 answersCancer biomarkers are measurable molecular indicators that can be used for various purposes in cancer research and clinical practice. They can help in the early detection, accurate diagnosis, prognosis, prediction of response to therapy, and monitoring of cancer patients. These biomarkers can be genetic variants, epigenetic signatures, transcriptional changes, or proteomic signatures, and can be detected in various samples such as tissues, blood, saliva, urine, etc.. Advances in detection technologies, such as next-generation sequencing and nanotechnology, have greatly improved the identification and analysis of cancer biomarkers. However, there is still a need for further improvement in developing biomarkers with greater sensitivity, specificity, and positive predictive value. The use of cancer biomarkers can contribute to precision oncology by identifying subsets of patients who are likely to benefit from targeted therapies. Overall, cancer biomarkers play a crucial role in improving cancer management and patient outcomes.
Except glucose and glutamine, what other metabolites are dysregulated in cancer cells?2 answersCancer cells dysregulate metabolites beyond glucose and glutamine. Lipids, including cholesterol and its derivatives, play important roles in cancer cell metabolism within harsh tumor microenvironments. Cancer cells also undergo metabolic reprogramming in one-carbon metabolism, which is critical for nucleotide synthesis, methylation reactions, and the generation of reducing cofactors. Additionally, altered metabolism in cancer cells involves glycolysis, leading to increased expression of enzymes responsible for glucose metabolism such as hexokinase, pyruvate kinase, and lactate dehydrogenase-A. Furthermore, cancer cells utilize strategic pathways like glycolysis and lipid metabolism for survival and progression, providing them with multimodal advantages over normal cells. Overall, cancer cells dysregulate lipids, one-carbon metabolism, and glycolysis in addition to glucose and glutamine to meet their energy demands and support tumor growth.